NCT00915590

Topical IL-1-Ra for Treatment of Corneal Neovascularization

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Reza Dana, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.

Detailed description

Normally avascular, under many pathologic conditions, vessels may invade the cornea from the limbal vascular plexus. Infection, inflammation, ischemia, degeneration, or trauma, and the loss of the limbal stem cell barrier can cause corneal neovascularization. Growth of new vessels may result in corneal scarring, edema, lipid deposition, and inflammation that may alter visual acuity and is a leading cause of monocular visual impairment and blindness. Additionally, it results in the loss of immune response across the cornea, thereby worsening the prognosis of a subsequent penetrating keratoplasty (PK). Growth of new blood and lymphatic vessels from preexisting vessels are mediated by members of the vascular endothelial growth factor (VEGF) family. This study is designed to investigate whether Interleukin-1-Receptor Antagonist is a drug that is both safe and effective in blocking VEGF pathways, stopping new growth, and reducing old vessel growth.

Conditions

• Corneal Neovascularization

Interventions

Type	Name	Description
DRUG	Placebo	Custom eye drop eye three times a day in both eyes for a period of 6 weeks
DRUG	IL-1Ra	5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks

Timeline

• Start date: 2009-04-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2009-06-08
• Last updated: 2017-05-08
• Results posted: 2017-05-08

Locations

1 site across 1 country: United States